{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:14:51Z","timestamp":1792440891925,"version":"4.5.0"},"reference-count":160,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2022.10.063","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T16:57:02Z","timestamp":1669741022000},"page":"36-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions"],"prefix":"10.1016","volume":"41","author":[{"given":"Keith M.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Willer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Tavares-Da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2022.10.063_b0005","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/infdis\/jiz652","article-title":"The epidemiology of herpes zoster in immunocompetent, unvaccinated adults \u226550 years old: Incidence, complications, hospitalization, mortality, and recurrence","volume":"222","author":"Tseng","year":"2020","journal-title":"J Infect Dis"},{"issue":"33","key":"10.1016\/j.vaccine.2022.10.063_b0010","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States","volume":"36","author":"Curran","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.10.063_b0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","article-title":"Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013","volume":"36","author":"McLaughlin","year":"2015","journal-title":"J Prim Prev"},{"issue":"11","key":"10.1016\/j.vaccine.2022.10.063_b0020","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.063_b0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Herpes zoster","volume":"369","author":"Solomon","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.10.063_b0030","doi-asserted-by":"crossref","unstructured":"Yanni EA, Ferreira G, Guennec M, El Hahi Y, El Ghachi A, Haguinet F, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open 2018;8:e020528.","DOI":"10.1136\/bmjopen-2017-020528"},{"key":"10.1016\/j.vaccine.2022.10.063_b0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000504484","article-title":"Herpes zoster and its prevention by vaccination","volume":"43","author":"Johnson","year":"2020","journal-title":"Interdiscip Top Gerontol Geriatr"},{"key":"10.1016\/j.vaccine.2022.10.063_b0040","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2022.10.063_b0045","doi-asserted-by":"crossref","unstructured":"Khan N, Patel D, Trivedi C, Shah Y, Lichtenstein G, Lewis J, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: A nationwide cohort study. Clin Gastroenterol Hepatol 2018;16:1919-27.e3.","DOI":"10.1016\/j.cgh.2017.12.052"},{"key":"10.1016\/j.vaccine.2022.10.063_b0050","article-title":"Quantification of risk factors for herpes zoster: population based case-control study","volume":"348","author":"Forbes","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2022.10.063_b0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","article-title":"Incidence of herpes zoster in patients with altered immune function","volume":"42","author":"Chen","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2022.10.063_b0060","series-title":"Herpes zoster: Postherpetic Neuralgia and other complications: Focus on treatment and prevention: Adis","author":"Watson","year":"2017"},{"key":"10.1016\/j.vaccine.2022.10.063_b0065","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1186\/s12879-020-05648-6","article-title":"Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009\u20132014","volume":"20","author":"Munoz-Quiles","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.10.063_b0070","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1086\/342963","article-title":"Varicella-zoster virus: atypical presentations and unusual complications","volume":"186","author":"Gnann","year":"2002","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.10.063_b0075","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1016\/j.transproceed.2012.09.090","article-title":"Disseminated varicella zoster virus infection in adult renal transplant recipients: outcome and risk factors","volume":"44","author":"Rommelaere","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.vaccine.2022.10.063_b0080","doi-asserted-by":"crossref","first-page":"101016","DOI":"10.1016\/j.pmedr.2019.101016","article-title":"Varicella-zoster virus post-exposure management and prophylaxis: A review","volume":"16","author":"Lachiewicz","year":"2019","journal-title":"Prev Med Rep"},{"key":"10.1016\/j.vaccine.2022.10.063_b0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.puhe.2016.10.013","article-title":"Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK","volume":"142","author":"Varghese","year":"2017","journal-title":"Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2022.10.063_b0090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/ciw296","article-title":"Increasing incidence of herpes zoster over a 60-year period from a population-based study","volume":"63","author":"Kawai","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2022.10.063_b0095","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.vaccine.2022.10.063_b0100","series-title":"Management of infections in the immunocompromised host","author":"Segal","year":"2018"},{"key":"10.1016\/j.vaccine.2022.10.063_b0105","doi-asserted-by":"crossref","unstructured":"Pergam SA, Limaye AP. Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33:e13622.","DOI":"10.1111\/ctr.13622"},{"key":"10.1016\/j.vaccine.2022.10.063_b0110","doi-asserted-by":"crossref","unstructured":"Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis 2021;15:879\u2013913.","DOI":"10.1093\/ecco-jcc\/jjab052"},{"key":"10.1016\/j.vaccine.2022.10.063_b0115","unstructured":"GlaxoSmithKline. Zovirax EU Summary of Product Characteristics (SmPC). Updated Oct 2020."},{"key":"10.1016\/j.vaccine.2022.10.063_b0120","unstructured":"GlaxoSmithKline. Shingrix EU Summary of Product Characteristics (SmPC). Updated March 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0125","unstructured":"GlaxoSmithKline. Shingrix US Prescribing Information (PI). Revised August 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0130","unstructured":"Merck. Zostavax EU Summary of Product Characteristics (SmPC). Updated May 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0135","unstructured":"Merck. Zostavax US Prescribing Information (PI). Revised January 2019."},{"issue":"40","key":"10.1016\/j.vaccine.2022.10.063_b0140","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1016\/j.vaccine.2020.07.049","article-title":"A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18\u201349 year old patients","volume":"38","author":"Racine","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.063_b0145","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/cid\/ciz1090","article-title":"Herpes zoster risk in immunocompromised adults in the United States: A systematic review","volume":"71","author":"McKay","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.10.063_b0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0950268801005921","article-title":"Epidemiology of varicella zoster virus infection in Canada and the United Kingdom","volume":"127","author":"Brisson","year":"2001","journal-title":"Epidemiol Infect"},{"issue":"8","key":"10.1016\/j.vaccine.2022.10.063_b0155","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.vaccine.2022.10.063_b0160","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.063_b0165","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbmt.2016.12.620","article-title":"Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies","volume":"23","author":"Sahoo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.vaccine.2022.10.063_b0170","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2009.263","article-title":"Vaccination of hematopoietic cell transplant recipients","volume":"44","author":"Ljungman","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.063_b0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.10.063_b0180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: A randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"issue":"10135","key":"10.1016\/j.vaccine.2022.10.063_b0185","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Winston","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vaccine.2022.10.063_b0190","first-page":"1610","article-title":"Duration of Antiviral Prophylaxis and Risk of Herpes Zoster among Patients Receiving Autologous Hematopoietic Stem Cell Transplants: A Retrospective","volume":"34","author":"Zhang","year":"2017","journal-title":"Observational Study Adv Ther"},{"key":"10.1016\/j.vaccine.2022.10.063_b0195","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1399-3062.2007.00289.x","article-title":"Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis","volume":"10","author":"Arness","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0200","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/QAI.0b013e318266cd3c","article-title":"Herpes zoster among persons living with HIV in the current antiretroviral therapy era","volume":"61","author":"Blank","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.063_b0205","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.rdc.2016.09.010","article-title":"Incidence and prevention of herpes zoster reactivation in patients with autoimmune diseases","volume":"43","author":"Chakravarty","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.vaccine.2022.10.063_b0210","doi-asserted-by":"crossref","unstructured":"Chang K, Lee HS, Kim YJ, Kim SO, Kim SH, Lee SH, et al. Increased risk of herpes zoster infection in patients with inflammatory bowel diseases in Korea. Clin Gastroenterol Hepatol 2018;16:1928-36.e2.","DOI":"10.1016\/j.cgh.2018.05.024"},{"issue":"5","key":"10.1016\/j.vaccine.2022.10.063_b0215","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ibd\/izy311","article-title":"Herpes zoster incidence in inflammatory bowel disease patients: A population-based study","volume":"25","author":"C\u00f4t\u00e9-Daigneault","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.10.063_b0220","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0225","doi-asserted-by":"crossref","unstructured":"Habel LA, Ray GT, Silverberg MJ, Horberg MA, Yawn BP, Castillo AL, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev 2013;22:82\u201390.","DOI":"10.1158\/1055-9965.EPI-12-0815"},{"issue":"12","key":"10.1016\/j.vaccine.2022.10.063_b0230","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/bjc.2017.124","article-title":"Herpes zoster risk after 21 specific cancers: population-based case-control study","volume":"116","author":"Hansson","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.063_b0235","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13555-018-0268-8","article-title":"Burden of herpes zoster in the Japanese population with immunocompromised\/chronic disease conditions: Results from a cohort study claims database from 2005\u20132014","volume":"9","author":"Imafuku","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.vaccine.2022.10.063_b0240","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/ibd\/izx115","article-title":"The severity of herpes zoster in inflammatory bowel disease patients treated with anti-TNF agents","volume":"24","author":"Khan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.063_b0245","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/tid.12149","article-title":"Incidence and risk factors for herpes zoster following heart transplantation","volume":"16","author":"Koo","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0250","doi-asserted-by":"crossref","first-page":"e25292","DOI":"10.1097\/MD.0000000000025292","article-title":"The incidence of herpes zoster in patients with diabetes mellitus: A meta-analysis of cohort studies","volume":"100","author":"Lai","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2022.10.063_b0255","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/apt.12182","article-title":"Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease","volume":"37","author":"Long","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2022.10.063_b0260","doi-asserted-by":"crossref","first-page":"e8746","DOI":"10.1097\/MD.0000000000008746","article-title":"Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: A retrospective cohort study","volume":"96","author":"Mao","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2022.10.063_b0265","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.puhe.2018.10.015","article-title":"Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain","volume":"167","author":"Mareque","year":"2019","journal-title":"Public Health"},{"key":"10.1016\/j.vaccine.2022.10.063_b0270","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12879-018-3121-x","article-title":"Risk and impact of herpes zoster among COPD patients: a population-based study, 2009\u20132014","volume":"18","author":"Munoz-Quiles","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0275","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ibd\/izy249","article-title":"Herpes zoster infection and herpes zoster vaccination in a population-based sample of persons with IBD: Is there still an unmet need?","volume":"25","author":"Nugent","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0280","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12879-015-1038-1","article-title":"Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis","volume":"15","author":"Pavlopoulou","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0285","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1399-3062.2010.00547.x","article-title":"Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients","volume":"13","author":"Pergam","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0290","doi-asserted-by":"crossref","first-page":"333","DOI":"10.5009\/gnl18304","article-title":"Increased risk of herpes zoster in young and metabolically healthy patients with inflammatory bowel disease: A nationwide population-based study","volume":"13","author":"Soh","year":"2019","journal-title":"Gut Liver"},{"key":"10.1016\/j.vaccine.2022.10.063_b0295","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/ciu498","article-title":"Vaccination against zoster remains effective in older adults who later undergo chemotherapy","volume":"59","author":"Tseng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0300","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.vaccine.2022.10.063_b0305","doi-asserted-by":"crossref","first-page":"E275","DOI":"10.1503\/cmaj.101137","article-title":"Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study","volume":"183","author":"Yang","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2022.10.063_b0310","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12879-015-0810-6","article-title":"The epidemiology of herpes zoster and its complications in Medicare cancer patients","volume":"15","author":"Yenikomshian","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0315","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","article-title":"Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease","volume":"4","author":"Gupta","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2022.10.063_b0320","doi-asserted-by":"crossref","unstructured":"Marra F, Lo E, Kalashnikov V, Richardson K. Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: A systematic review and meta-analysis. Open Forum Infect Dis 2016;3:ofw205.","DOI":"10.1093\/ofid\/ofw205"},{"key":"10.1016\/j.vaccine.2022.10.063_b0325","doi-asserted-by":"crossref","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis. Gastroenterology 2020;158:1554-73.e12.","DOI":"10.1053\/j.gastro.2020.01.001"},{"key":"10.1016\/j.vaccine.2022.10.063_b0330","article-title":"Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know","author":"Schreiner","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0335","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.vaccine.2022.10.063_b0340","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-021-01057-z","article-title":"Safety of S1P modulators in patients with immune-mediated diseases: A systematic review and meta-analysis","volume":"44","author":"Lasa","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2022.10.063_b0345","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.vaccine.2022.10.063_b0350","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-020-02399-2","article-title":"Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data","volume":"23","author":"Simon","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.vaccine.2022.10.063_b0355","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13223-020-00453-x","article-title":"Asthma increases the risk of herpes zoster: a nested case-control study using a national sample cohort","volume":"16","author":"Kim","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.vaccine.2022.10.063_b0360","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2015.10.032","article-title":"Asthma as a risk factor for zoster in adults: A population-based case-control study","volume":"137","author":"Kwon","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2022.10.063_b0365","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/02770903.2016.1211142","article-title":"Adult asthma is associated with an increased risk of herpes zoster: A population-based cohort study","volume":"54","author":"Peng","year":"2017","journal-title":"J Asthma"},{"key":"10.1016\/j.vaccine.2022.10.063_b0370","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.10.063_b0375","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0380","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1080\/21645515.2019.1627818","article-title":"Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials","volume":"15","author":"Oostvogels","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.10.063_b0385","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1093\/ofid\/ofaa439.082","article-title":"Safety profile of the adjuvanted recombinant zoster vaccine (RZV) in immunocompromised populations: An overview of 6 trials","volume":"7","author":"Fauqued","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0390","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","article-title":"Risk of Guillain-Barr\u00e9 Syndrome following recombinant zoster vaccine in Medicare beneficiaries","volume":"181","author":"Goud","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2022.10.063_b0395","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1016\/j.vaccine.2018.08.080","article-title":"Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals","volume":"36","author":"Meyers","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.063_b0400","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","article-title":"Assessment of the potential public health impact of Herpes Zoster vaccination in Germany","volume":"13","author":"Curran","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.10.063_b0405","doi-asserted-by":"crossref","first-page":"e037458","DOI":"10.1136\/bmjopen-2020-037458","article-title":"Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study","volume":"10","author":"Andrews","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2022.10.063_b0410","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1080\/21645515.2021.1953346","article-title":"Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice","volume":"17","author":"Stadtmauer","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.10.063_b0415","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/bloodadvances.2020003749","article-title":"Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation","volume":"5","author":"Baumrin","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.vaccine.2022.10.063_b0420","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2022.10.063_b0425","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.10.063_b0430","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.10.063_b0435","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","volume":"34","author":"Chlibek","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.063_b0440","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bbmt.2013.11.013","article-title":"Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients","volume":"20","author":"Issa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.vaccine.2022.10.063_b0445","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ajh.22196","article-title":"Experience with use of Zostavax((R)) in patients with hematologic malignancy and hematopoietic cell transplant recipients","volume":"87","author":"Naidus","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.vaccine.2022.10.063_b0450","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41409-018-0112-x","article-title":"Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation","volume":"53","author":"Pandit","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.vaccine.2022.10.063_b0455","unstructured":"Clinicaltrials.gov. Serologic response to SHINGRIX vaccine in patients with CLL and WM treated with BTK inhibitors (NCT03771157). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03771157 Accessed June 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0460","unstructured":"Clinicaltrials.gov. Response to the SHINGRIX varicella zoster virus (VZV) vaccine in chronic lymphocytic leukemia (CLL) and CLL treated with Bruton's Tyrosine Kinase inhibitor (BTK-I) (NCT03702231). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03702231 Accessed June 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0465","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.2020008758","article-title":"Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines","volume":"137","author":"Pleyer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2022.10.063_b0470","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial","volume":"125","author":"Vink","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2022.10.063_b0475","unstructured":"clinicaltrials.gov. ZOSTAVAX in persons imminently receiving chemotherapy for solid organ tumors (NCT02444936); 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0480","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3 Randomized Clinical Trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0485","unstructured":"clinicaltrials.gov. ZOSTAVAX\u00ae in renal transplant patients (NCT01137669). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01137669 Access July 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0490","unstructured":"clinicaltrials.gov. Safety and immunogenicity of zostavax vaccine in patients undergoing living donor kidney transplantation (NCT00940940). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00940940 Accessed July 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0495","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0500","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/cid\/ciy242","article-title":"Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells\/mL Virologically Suppressed on Antiretroviral Therapy","volume":"67","author":"Benson","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0505","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.vaccine.2022.10.063_b0510","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: A retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vaccine.2022.10.063_b0515","unstructured":"clinicaltrials.gov. Subunit vaccine against herpes zoster in RA patients treated with JAK-inhibitors (VACCIMIL-ZOSTER) (NCT03886038). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03886038 Accessed July 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0520","unstructured":"clinicaltrials.gov. Safety of zostavax vaccination in rheumatoid arthritis (NCT01506661); 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0525","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1016\/j.vaccine.2021.05.043","article-title":"Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease","volume":"39","author":"Kochhar","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.063_b0530","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.cgh.2021.07.023","article-title":"Efficacy of recombinant zoster vaccine in patients with inflammatory bowel disease","volume":"20","author":"Khan","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2022.10.063_b0535","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s10620-019-06016-4","article-title":"Safety of recombinant zoster vaccine in patients with inflammatory bowel disease","volume":"65","author":"Satyam","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.vaccine.2022.10.063_b0540","unstructured":"Clinicaltrials.gov. Immunogenicity of herpes zoster subunit vaccine in inflammatory bowel disease patients treated with vedolizumab (NCT03798691). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03798691 Accessed July 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0545","unstructured":"clinicaltrials.gov. Shingrix vaccine in patients with moderate to severe ulcerative colitis on tofacitinib (NCT03591770). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03591770 Accessed July 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0550","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.cgh.2018.10.016","article-title":"Efficacy of live attenuated herpes zoster vaccine in patients with inflammatory bowel diseases","volume":"17","author":"Khan","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2022.10.063_b0555","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0560","unstructured":"clinicaltrials.gov. Recombinant zoster vaccine in stable SLE patients (NCT04516408); 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0565","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.7326\/M20-6928","article-title":"The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy : A randomized controlled trial","volume":"174","author":"Curtis","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2022.10.063_b0570","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jinf.2013.04.010","article-title":"Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus","volume":"67","author":"Hata","year":"2013","journal-title":"J Infect"},{"issue":"832","key":"10.1016\/j.vaccine.2022.10.063_b0575","first-page":"e1","article-title":"Improving herpes zoster vaccination rates through use of a clinical pharmacist and a personal health record","volume":"126","author":"Otsuka","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.vaccine.2022.10.063_b0580","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.4161\/hv.25031","article-title":"Utilizing health information technology to improve vaccine communication and coverage","volume":"9","author":"Stockwell","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.10.063_b0585","first-page":"1","article-title":"The use of an EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease","volume":"360","author":"Reich","year":"2019","journal-title":"Crohn's Colitis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0590","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1016\/j.vaccine.2021.08.073","article-title":"Standardizing shared vaccination responsibilities among specialists to improve vaccination rates of immunosuppressed patients","volume":"39","author":"Bhat","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.063_b0595","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/ibd\/izab055","article-title":"Barriers to administering vaccines in inflammatory bowel disease centers","volume":"27","author":"Bhat","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.vaccine.2022.10.063_b0600","article-title":"How to implement a successful vaccination program in outpatient gastroenterology practices: A focus on patients with inflammatory bowel disease and chronic liver disease","author":"Bhat","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2022.10.063_b0605","unstructured":"clinicaltrials.gov. Safety, tolerability, and immunogenicity of CRV-101 in healthy adult subjects; 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0610","unstructured":"clinicaltrials.gov. Study to assess the safety, tolerability and explore the immunogenicity of EG-HZ in healthy adult volunteers; 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0615","unstructured":"Vaccitech. Pipeline; 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0620","unstructured":"Science SI. Pipeline; 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0625","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1182\/bloodadvances.2020002269","article-title":"Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study","volume":"4","author":"Camargo","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.vaccine.2022.10.063_b0630","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/vaccines9030202","article-title":"Ageing of immune system and response to a live-attenuated herpes zoster vaccine in lung transplant candidates","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.10.063_b0635","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-143342","article-title":"High rates of varicella zoster virus antibody seroconversion and persistence after administration of the adjuvanted, recombinant varicella zoster vaccine in multiple myeloma patients undergoing active treatment","volume":"136","author":"Sweiss","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2022.10.063_b0640","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.10.063_b0645","unstructured":"Australian Technical Advisory Group on Immunisation. Statement on the clinical use of zoster vaccines in adults in Australia; 2022."},{"key":"10.1016\/j.vaccine.2022.10.063_b0650","unstructured":"Bundesministerium Soziales Gesundheit Pflege und Konsumentenschutz. Impfplan \u00d6sterreich; 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0655","unstructured":"CDC. Zostavax (Zoster Vaccine Live) Recommendations; 2020."},{"key":"10.1016\/j.vaccine.2022.10.063_b0660","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3947\/ic.2015.47.1.68","article-title":"Revised adult immunization guideline recommended by the korean society of infectious diseases, 2014","volume":"47","author":"Choi","year":"2015","journal-title":"Infect Chemother"},{"key":"10.1016\/j.vaccine.2022.10.063_b0665","unstructured":"Consejo Interterritorial del Sistema Nacional de Salud. Recomendaciones de vacunacion frente a herpes zoster; 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0670","unstructured":"Netherlands Health Council. Vaccinatie tegen gordelroos; 2019."},{"key":"10.1016\/j.vaccine.2022.10.063_b0675","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.10.063_b0680","unstructured":"Federal Vaccination Comission. Evaluation of vaccines and vaccination against herpes zoster (Zostavax\u00ae and Shingrix\u00ae); 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0685","article-title":"Vaccination against herpes zoster","author":"Superior Health","year":"2022","journal-title":"Brussels"},{"key":"10.1016\/j.vaccine.2022.10.063_b0690","unstructured":"Haut Conseil de la Sant\u00e9 Publique. Vaccination calendar and vaccination recommendations 2022; 2022."},{"key":"10.1016\/j.vaccine.2022.10.063_b0695","unstructured":"New Zealand Ministry of Health. Immunisation Handbook 2020; 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0700","unstructured":"Hong Kong Medical Association. Adult immunization; 2022."},{"key":"10.1016\/j.vaccine.2022.10.063_b0705","unstructured":"JCVI. Vaccination against shingles Information for healthcare practitioners. 2021;3."},{"key":"10.1016\/j.vaccine.2022.10.063_b0710","unstructured":"Malaysia MoH. Varicella-zoster viral infection; 2017."},{"key":"10.1016\/j.vaccine.2022.10.063_b0715","unstructured":"Ministry of Health. The recommended vaccination schedule for adults; 2014."},{"key":"10.1016\/j.vaccine.2022.10.063_b0720","unstructured":"Ministry of Health. Piano Nazionale Prevenzione Vaccinale PNPV 2017-2019; 2017."},{"key":"10.1016\/j.vaccine.2022.10.063_b0725","unstructured":"Ministry of Health. National Adult Vaccination Program 2018 - 2019; 2018."},{"key":"10.1016\/j.vaccine.2022.10.063_b0730","unstructured":"Ministry of Health. Immunization schedule; 2019."},{"key":"10.1016\/j.vaccine.2022.10.063_b0735","unstructured":"Ministry of Health. Shingles; 2022."},{"key":"10.1016\/j.vaccine.2022.10.063_b0740","unstructured":"National Health Care Institute. GVS advice RZV (Shingrix\u00ae) for the prevention of herpes zoster and related post-herpetic neuralgia; 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0745","unstructured":"National Immunisation Advisory Committee. Immunisation Guidelines Chapter 23 - Varicella Zoster; 2022."},{"key":"10.1016\/j.vaccine.2022.10.063_b0750","unstructured":"NCIRS. ATAGI recommendation for the use of Shingrix in immunocompetent adults aged \u226550 years; 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0755","unstructured":"World Health Organization. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec 2014;89:265\u201387."},{"key":"10.1016\/j.vaccine.2022.10.063_b0760","unstructured":"Pinto Neto L, Kfouri R. Vacina herpes-z\u00f3ster inativada recombinante (Shingrix\u00ae); 2022."},{"key":"10.1016\/j.vaccine.2022.10.063_b0765","unstructured":"Public Health Authority. Vaccine against shingles (herpes zoster); 2022."},{"key":"10.1016\/j.vaccine.2022.10.063_b0770","unstructured":"Comit\u00e9 sur l'immunisation du Qu\u00e9bec. Avis sur la pertinence d\u2019ajouter la vaccination contre le zona au Programme qu\u00e9b\u00e9cois d\u2019immunisation; 2020."},{"key":"10.1016\/j.vaccine.2022.10.063_b0775","unstructured":"Sanidad Md. Vacunas y Programa de Vacunaci\u00f3n; 2021."},{"key":"10.1016\/j.vaccine.2022.10.063_b0780","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00103-019-02882-5","article-title":"Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine : Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute","volume":"62","author":"Siedler","year":"2019","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"10.1016\/j.vaccine.2022.10.063_b0785","unstructured":"spole\u010dnost \u010cv. O\u010dkovac\u00ed kalend\u00e1\u0159 pro dosp\u011bl\u00e9 - podle v\u011bku; 2019."},{"key":"10.1016\/j.vaccine.2022.10.063_b0790","unstructured":"Infectious Disease Association of Thailand. Vaccination recommendations for adults and the elderly; 2018."},{"key":"10.1016\/j.vaccine.2022.10.063_b0795","doi-asserted-by":"crossref","first-page":"220","DOI":"10.14745\/ccdr.v44i09a06","article-title":"Summary of the NACI update on herpes zoster vaccines","volume":"44","author":"Warrington","year":"2018","journal-title":"Can Commun Dis Rep"},{"key":"10.1016\/j.vaccine.2022.10.063_b0800","unstructured":"ATAGI. Statement on the clinical use of zoster vaccines in older adults in Australia; 2021."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:21:24Z","timestamp":1759404084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22013299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":160,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X22013299"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.063","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}